A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Brexanolone (Primary)
- Indications Status epilepticus
- Focus Registrational; Therapeutic Use
- Acronyms STATUS
- Sponsors Sage Therapeutics
- 09 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 09 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
- 07 Aug 2017 According to a SAGE Therapeutics media release, status changed from recruiting to active, no longer recruiting.